trans-S-(1-Propenyl)-L-cysteine | 7683-75-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: trans-S-(1-Propenyl)-L-cysteine
• 英文别名: 2-amino-3-[(Z)-prop-1-enyl]sulfanylpropanoic acid
• CAS: 7683-75-2；15042-84-9；15042-98-5；52438-09-2；57760-74-4
• 化学式: C₆H₁₁NO₂S
• 分子量: 161.225
• InChiKey: HYGGRRPFVXHQQW-IHWYPQMZSA-N

物化性质

• 熔点：
  172.1 °C
• 沸点：
  301.1±37.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  88.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• NMR imaging with Mn(II) coordination compositions
  申请人：SALUTAR, INC.

  公开号：EP0308983A2

  公开（公告）日：1989-03-29

  Enhanced T₁ and T₂ relaxation in NMRI is obtained with solutions of non-chelate coordination compounds of the formula: [Mn(II)(H₂O)mA1nA2oA3pA4q]+a(Y,Zr)-a In the formula, A1, A2, A3 and A4 are the same of different amino-substituted carboxylic acid groups having from 2 to 18 carbons; Y and Z are each the same or a different anion of a pharmaceutically acceptable inorganic acid or an organic carboxylic acid having from 2 to 18 carbons; a is valence of the ions; m, n, o, p, and q are each 1 or 0, (m + n + o + p + q) = 4, and (n + o + p + q) is preferably from 1 to 3; and r is 1, and if Y is a multivalent anion, r is 0 or 1. The solution has a pH within the range of from 4 to 9.5, preferably from 5 to 7, and optimally from 5 to 6.5, and for parenteral administration, a coordination compound concentration of from 0.5 to 4.0 wt%. Preferably, n is from 1 to 3, optimally from 2-4, and most optimally from 2 to 3, and Y and Z are monovalent. For example Y is preferably an anion of an aliphatic carboxylic acid having from 2 to 6 carbons such as acetic, propionic, n-butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid or gluconic acid, and Z is an inorganic anion such as chloride or sulfate. A1, A2, A3 and A4 are preferably α-amino acids having from 2 to 6 carbons such as glycine.

  利用式中的非螯合物配位化合物溶液，可以增强 NMRI 中的 T₁ 和 T₂ 弛豫： [Mn(II)(H₂O)mA1nA2oA3pA4q]+a(Y,Zr)-a 式中 A1、A2、A3 和 A4 是具有 2 至 18 个碳原子的相同或不同的氨基取代的羧酸基团； Y 和 Z 分别是相同或不同的药学上可接受的无机酸阴离子或具有 2 至 18 个碳原子的有机羧酸阴离子； a 是离子的化合价； m、n、o、p 和 q 各为 1 或 0，（m + n + o + p + q）= 4，（n + o + p + q）最好为 1 至 3；以及 r 为 1，如果 Y 是多价阴离子，则 r 为 0 或 1。 溶液的 pH 值范围为 4 至 9.5，优选 5 至 7，最佳为 5 至 6.5，对于肠外给药，配位化合物的浓度为 0.5 至 4.0 wt%。n 最好为 1 至 3，最佳为 2 至 4，最理想为 2 至 3，Y 和 Z 为一价。例如，Y 最好是具有 2 至 6 个碳原子的脂肪族羧酸的阴离子，如乙酸、丙酸、正丁酸、异丁酸、戊酸、异戊酸、特戊酸或葡萄糖酸，Z 是无机阴离子，如氯化物或硫酸盐。A1、A2、A3 和 A4 最好是具有 2 至 6 个碳原子的 α-氨基酸，如甘氨酸。
• Alphavirus vectors for influenza virus vaccines
  申请人：Novartis Vaccines and Diagnostics, Inc.

  公开号：EP2848692A1

  公开（公告）日：2015-03-18

  Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.

  本文描述的是刺激对一种或多种源自一种或多种呼吸道病原体的蛋白质的免疫反应的组合物和方法。特别是，本发明涉及α-病毒复制子、α-病毒载体构建体、表达一种或多种源自一种或多种呼吸道病原体的抗原的α-病毒复制子颗粒，以及制造和使用这些免疫原组合物的方法。
• Chimeric alphavirus replicon particles
  申请人：Chiron Corporation

  公开号：US20030232324A1

  公开（公告）日：2003-12-18

  Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.

  提供了嵌合字母病毒和字母病毒复制子颗粒，包括其制造和使用方法。具体来说，所提供的α病毒颗粒具有来自一种或多种α病毒的核酸分子和来自至少两种或多种α病毒的结构蛋白（囊膜和/或包膜）。公开了含有嵌合字母病毒颗粒的制造、使用和治疗制剂的方法。
• Hiv envelope-cd4 complexes and hybrids
  申请人：Barnett Susan

  公开号：US20060073576A1

  公开（公告）日：2006-04-06

  Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are important in virus neutralization. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.

  已公开的 Env-CD4 复合物和杂交种可暴露出对病毒中和非常重要的隐性表位。还提供了使用多核苷酸和多肽进行诊断、治疗和预防的方法。
• METHOD FOR DERMALLY ADMINISTERING POLYPEPTIDES
  申请人：ALZA CORPORATION

  公开号：EP1030688B1

  公开（公告）日：2004-09-29